Immuno-oncology now represents a real therapeutic breakthrough and is still rapidly evolving. Within just a few years, immunotherapies have been approved as an important treatment option for many cancer patients.
Pharmaceutical and biotech companies face significant pressure to accelerate immuno-oncology drug candidates from discovery to clinical use. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Comprehensively addressing pharmacology issues, compound manufacturing, toxicology strategy, and designing appropriate clinical trials can result in accelerating immuno-oncology products development, mitigating timelines, costs and regulatory risks.
This free event will focus on a number of key considerations for transitioning an immuno-oncology product from discovery to clinical trials, including:
- Efficiency assessment in tumor models,
- Toxicology and safety evaluation
- Clinical trial design
The final program will be available soon.